Skip to main content
PLOS One logoLink to PLOS One
. 2021 May 17;16(5):e0251549. doi: 10.1371/journal.pone.0251549

Perioperative pupil size in low-energy femtosecond laser-assisted cataract surgery

Alireza Mirshahi 1,*, Astrid Schneider 2, Catharina Latz 1, Katharina A Ponto 3,4
Editor: Yu-Chi Liu5
PMCID: PMC8128224  PMID: 33999970

Abstract

Purpose

To assess potential changes in pupil size during femtosecond laser-assisted cataract surgery (FLACS) using a low-energy laser system.

Methods

The pupil sizes of eyes undergoing FLACS were measured using the Ziemer LDV Z8 by extracting images from the laser software after each of the following steps: application of suction, lens fragmentation, and capsulotomy. Furthermore, the pupil diameters were measured based on preoperative surgical microscope images and after releasing the suction. Paired t-test and the two one-sided tests (TOST) procedure were used for statistical analyses. The horizontal and vertical pupil diameters were compared in each of the steps with preoperative values.

Results

Data were available for 52 eyes (52 patients, mean age 73.4 years, range 51–87 years). The equivalence between mean preoperative pupil size and status immediately after femtosecond laser treatment was confirmed (p<0.001; 95% confidence interval [−0.0637, 0.0287] for horizontal and p<0.001; 95% CI [−0.0158, 0.0859] for vertical diameter). There was statistically significant horizontal and vertical enlargement of pupil diameters between 0.15 and 0.24 mm during the laser treatment steps as compared with preoperative values (all p values <0.001).

Conclusions

No progressive pupil narrowing was observed using low-energy FLACS. Although a suction-induced, slight increase in pupil area became apparent, this effect was completely reversible after removing the laser interface.

Introduction

During the past decade, femtosecond laser-assisted cataract surgery (FLACS) has gained increasing popularity [14]. However, its automation and precision come at a price [5,6]. One of these costs is miosis induction. This phenomenon has been described in several studies using different laser platforms [7,8] and is believed to be induced by increased levels of prostaglandin E2 (PGE2) measured at the end of laser pretreatment [710]. Currently, preoperative administration of nonsteroidal anti-inflammatory drugs (NSAIDs) is recommended to overcome the alteration of pupil size [9,10]. In their assessment of the Catalys Precision Laser System, Jun et al. reported a correlation between the degree of miosis and patient age, time for lens fragmentation, and time for main incision creation [8]. However, according to our personal experience in the clinic we hypothesized that no miosis induction through laser pretreatment occurs when using the Ziemer Z8 laser. This could be because of the Ziemer Z8 inherent low-energy–high-frequency laser technology. Conventional “high-energy” femtosecond lasers emit pulses with an energy in the 4 to 15 μJ range [5,7,11], whereas the newer low-energy technology uses high-pulse repetition rates greater than 1 MHz and a low-pulse energy in the nanojoule range [12]. This is achieved using a high numerical aperture in the laser-focusing optics, enabling small laser spot sizes [13].

This study aims to better understand the possible factors influencing changes in pupil size in FLACS, by analyzing pupil size at different surgical time points.

Materials and methods

Fifty-two eyes of 52 patients undergoing routine FLACS were included in this retrospective study. The patients’ age, laterality of surgery, and special notes in the surgery report were extracted for analysis as well as all known ocular comorbidities such as pseudoexfoliation syndrome and glaucoma. Axial length, anterior chamber depth, lens thickness, and white-to-white distance were obtained from laser biometry performed on the day of surgery (IOLMaster 700, Carl Zeiss Meditec). If both eyes were eligible for the study, only the data from the first operated eye were used. This study was performed according to the tenets of the Declaration of Helsinki and did not require approval of an independent ethics committee, as ruled by the North Rhine Medical Chamber.

Pupil size

Retrospectively, the images of the top-view camera that were integrated into the laser handpiece and taken automatically during the liquid interface docking of the eye were analyzed with regard to the horizontal and vertical pupil diameters at the following surgical time points: immediately after application of the vacuum docking suction, after completion of lens fragmentation, and after completion of laser capsulotomy. In addition, the diameters of the pupils before surgery and after release of suction and removal of the laser handpiece were measured by analyzing the images from the video recordings taken through the surgical microscope.

Normalization of pupil diameter raw data for cornea magnification in different media

When the pupil is observed under a surgical microscope by looking through the cornea, the refractive power of the cornea magnifies the pupil, unlike objects outside the cornea, such as the limbus. Although the laser handpiece is docked to the eye, the space above the cornea is filled with a balanced salt solution (BSS) instead of air, as with microscopy. This results in a reduction in the refractive power of the cornea–BSS interface as compared to the cornea–air interface due to the change in the index of the refraction difference (Fig 1).

Fig 1. Illustration of the difference in magnification when observing the pupil through the cornea (a) by microscope through the air–cornea interface versus (b) during liquid interface laser docking.

Fig 1

The resulting change in magnification was modeled using ZEMAX ray-tracing software and the Liou-Brennan eye model [14]. A correction factor to compensate for the reduced pupil magnification in the images taken by the laser was determined and applied to the measured raw pupil diameters.

Surgical technique

One single experienced cataract surgeon (A.M.) performed all FLACS procedures using the Ziemer LDV Z8 (Ziemer Ophthalmic System) and an Alcon Centurion phacoemulsification system (Alcon Lab.). All surgeries were performed at the Dardenne Eye Hospital in Bonn, Germany.

Routine preoperative care included mydriatic treatment consisting of tropicamide 5 mg/mL (Mydriaticum Stulln® UD, Pharma Stulln GmbH) and phenylephrine 5% (Neosynephrin-POS® 5%, Ursapharm Arzneimittel GmbH) eye drops, four times each. NSAIDs were not administered to any patient. All surgeries were performed under peribulbar anesthesia (each 3 ml of Mepivacaine 2% and Bupivacaine 0.75% and 75 IE hyaluronidase with a 22 Gauge needle) with the surgeon sitting at the 12 o’clock position and the Ziemer Femto LDV Z8 positioned at an oblique angle. After disinfection and sterile draping, the femtosecond laser interface was docked, and vacuum suction was applied (approximately 420 mbar). Standard laser parameters were a 6 mm diameter laser lens fragmentation in six segments at 105% laser energy, followed by a 5.2 mm capsulotomy diameter using 90% laser energy. Suction was released after the completion of capsulotomy, and the laser was moved aside. All subsequent surgical steps were performed under a surgical microscope (Zeiss). A posterior limbal main incision of 2.8 mm width and two 1.1 mm paracenteses were made. Dispersive viscoelastic was introduced into the anterior chamber. The laser-precut capsulotomy was removed using Utrata forceps. The lens was hydrodissected from the capsule, and the nucleus was hydrodelineated. The nucleus was removed using high-vacuum phacoemulsification. Cortex aspiration, polishing of the posterior capsule, and removal of the viscoelastic device after implantation of the intraocular lens were performed using a bimanual irrigation-aspiration system. At the end of surgery, the paracenteses were hydrated and controlled for water tightness.

Statistical analyses

Normally distributed continuous variables are described using mean ± standard deviation (SD), minimum, and maximum. Skewed variables are described using median, 25%, and 75% quartile. Boxplots of the individual values as well as the difference from the first value (before surgery) are presented. Categorical variables are described using relative and absolute frequencies.

The main question to address was whether the measures “before surgery” and “released suction,” each measured on the same subject, were equivalent; that is, whether they differed on average by a small margin. A difference of >|0.2 mm| was assumed to be clinically relevant. Thus, an equivalence range of [−0.2, 0.2] was fixed. To test a possible equivalence between two measurements, the two one-sided tests (TOST) method was carried out, according to the work by Schuirmann [15,16]. For this, TOST were determined to reject the null hypotheses mu < 0.2 and mu > −0.2. If both null hypotheses can be rejected, the equivalence to the given range is proven. In addition, the 90% confidence interval of the difference is given. These were confirmatory analyses with a global significance level of 5%. To determine how the individual differences behave compared with the pupil diameter, a mean difference plot was also generated.

A secondary question was whether the values measured during different steps of the laser pretreatment varied from the initial values. Whether the effect was clinically relevant or whether equivalence could still be assumed were investigated. Two-sided paired t-tests were performed to investigate these differences. In addition, a possible equivalence with an equivalence range [−0.2, 0.2] was investigated using the TOST method. No significance-level adjustments were made for the secondary questions. The p values were used for descriptive purposes. The statistical evaluation was carried out using the software program R, version 3.5.3 (http://www.R-project.org).

Results

Complete data were available for 52 eyes of 52 patients (mean age 73.4 years, range 51–87 years; 19 right and 33 left eyes). Glaucoma was diagnosed preoperatively in four eyes (7.7%), and pseudoexfoliation was diagnosed in five eyes (9.6%). Further descriptive data, including axial length, anterior chamber depth, lens thickness, and white-to-white distance, are illustrated in Table 1.

Table 1. Preoperative morphologic parameters in 52 eyes undergoing low-energy Femtosecond-Laser-Assisted Cataract Surgery (FLACS).

Preoperative parameter Mean ± standard deviation (mm) Median (mm) Minimum (mm) Maximum (mm)
Axial length 24.06 ± 1.35 24.10 21.34 27.13
Anterior chamber depth 3.23 ± 0.4 3.26 2.39 4.01
Lens thickness 4.62 ± 0.4 4.67 3.69 5.34
White-to-white distance 11.99 ± 0.46 12.0 10.8 12.8

The mean (±SD), median [minimum-maximum] preoperative values were 7.06 (±0.66), 7.12 [5.5–8.27 mm], respectively, for horizontal pupil diameter and 7.16 (±0.65) mm, 7.12 [5.75–8.46 mm], respectively, for vertical pupil diameters. The changes in pupil diameters at the different time stages are shown in Table 2 and Fig 2.

Table 2. Intraoperative pupil diameters at different points in time (mean ± standard deviation).

Before surgery Suction applied Lens fragmentation completed Capsulotomy completed Suction released (laser completed)
Horizontal diameter (mm) 7.06 ± 0.66 7.20 ± 0.72 7.21 ± 0.71 7.24 ± 0.71 7.07 ± 0.65
Vertical diameter (mm) 7.16 ± 0.65 7.38 ± 0.71 7.40 ± 0.70 7.39 ± 0.71 7.13 ± 0.63

Fig 2. Changes in pupil diameters at different time points of low-energy Femtosecond-Laser-Assisted Cataract Surgery (FLACS) using the Ziemer LDV Z8.

Fig 2

Boxplots showing the vertical (a) and horizontal (b) pupil diameters (median, quartiles, minimum, and maximum) before surgery, immediately after application of suction, after completion of lens fragmentation, after completion of laser capsulotomy, and after release of suction.

The horizontal and vertical pupil diameters were equivalent when comparing preoperative measurement to post laser values; the mean horizontal difference between these values was −0.0175 mm. The TOST procedure confirmed that the difference was within the preset equivalent range of 0.2 mm (p<0.0001, 95% TOST interval [−0.0637, 0.0287]). The mean vertical difference between the stated values was 0.0351 mm. The TOST procedure confirmed that the difference was within the preset equivalent range of 0.2 mm (p<0.0001, 95% TOST interval [−0.0158, 0.08595]). Mean difference plots show that the mean and 95% TOST intervals were within the equivalence range (Fig 3).

Fig 3. Differences in the measures of the horizontal diameter (a) and vertical diameter (b) of the pupil before surgery and at the time point “released suction,” each measured on the same subject.

Fig 3

The mean differences and the 95% confidence intervals of the differences are within the equivalence range [−0.2, 0.2].

We could not detect any equivalence of the preoperative pupil diameters to those measured immediately after application of suction, after completion of lens fragmentation, or after completion of laser capsulotomy (suction applied during those measurements, TOST procedure, all p>0.05). As shown in detail in Table 3, there was a statistically significant enlargement of pupil diameters (between 0.15 and 0.24 mm) during laser treatment steps compared with preoperative values (paired t-test, all p values < 0.001).

Table 3. Statistical analyses of change in pupil diameter within laser application steps as compared with preoperatively (paired t-test; mean change, p value [95% confidence interval]).

A negative difference indicates increase in size as compared with the preoperative size.

Compared point in time Suction applied Lens fragmentation completed Capsulotomy completed
Horizontal diameter (mm) −0.145, p < 0.001, [−0.217, −0.073] −0.152, p < 0.001, [−0.228, −0.076] −0.183, p < 0.001, [−0.259, −0.108]
Vertical diameter (mm) −0.222, p < 0.001, [−0.305, −0.139] −0.238, p < 0.001, [−0.320, −0.155] −0.225, p < 0.001, [−0.306, −0.145]

Discussion

To the best of our knowledge, this is the first study to measure pupil diameters at various points of low-energy FLACS. The main finding is this research is that overall, no change in the size of the pupil dimensions was noted from before the operation to after laser treatment, and a reversible and mild increase in the pupil area was noted during the laser procedure itself. This is in contrast to various studies that found FLACS to be associated with pupillary constriction [5,8,1722]. In a previous study on low-energy FLACS with a smaller sample size, there was no statistically significant difference between the pupil areas measured preoperatively versus after laser treatment in the same surgical setting [23]. The current study confirmed these findings and furthermore analyzed the variations in pupil size during femtosecond laser application and under suction. The pupil size increased slightly under suction and then decreased to the preoperative level after suction was terminated. This is a physiologic phenomenon which is explained both by the afferent pupillary defect and also by an impairment in the iris sphincter (due to an intraocular pressure elevation greater than the systolic ophthalmic artery pressure) [24].

Femtosecond laser-induced miosis has been investigated in various studies [58,10,1722]. In particular, each study has attempted to elucidate causative factors. Prostaglandin release has been discussed as a causative agent for miosis, and increased amounts have been measured in FLACS compared to classic phacoemulsification cataract surgery [18,20,21,2527]. This was true for both low-energy, high-frequency as well as conventional femtosecond laser technology [8,21,27,28], although prostaglandin levels measured in low-energy, high-frequency FLACS were lower than in conventional FLACS. Consequently, pretreatment with NSAIDs before FLACS has been promoted and shown to reduce the prostaglandin surge, thereby decreasing FLACS-associated miosis [5,9,10,17,18,22,28]. Nevertheless, NSAID pretreatment does not appear to completely eliminate FLACS-induced miosis [18]. Therefore, additional causative agents were subsequently sought, and even technical details were examined to better understand this phenomenon. Bali et al. described a learning curve in his early experience with FLACS and found a miosis rate of 24% in his first 50 cases as opposed to 9.5% in the following 150 cases [11]. Suction time and docking attempts were significantly higher in the first 50 cases and were therefore postulated as causative factors of miosis. Similar results were reported by Roberts et al. when comparing the first 200 and subsequent 1300 cases [6]. In contrast, Jun found a 29% reduction in pupil area in 56 eyes undergoing high-energy FLACS [8]. This reduction was correlated with laser treatment duration, primary incision, and patient age but not with suction and shifting time (i.e., the time between the completion of femtosecond pretreatment and initiation of phacoemulsification). Although Schultz et al. [20] found no correlation between suction time and increased prostaglandin levels, Popiela et al. [19] reported significant miosis when suction time was longer than 2 minutes. Both groups used different laser systems (Catalys® and Victus®). Diakonis et al. compared three laser platforms (LenSx, Alcon Laboratories; Catalys, Abbott Medical Optics Inc.; and Victus, Bausch & Lomb, Inc.) and their effect on pupil diameter [12] and found a mean pupillary miosis of 1.42 ± 1.26 mm for the LenSx, 0.66 ± 0.89 mm for the Catalys, and 0.14 ± 0.34 mm for the Victus group [7]. The difference between the three groups was statistically significant.

Although all three laser platforms use high-energy technology, their patient interface systems and other parameters are different. This emphasizes the importance of obtaining a better understanding of the different factors that affect miosis induction and prostaglandin release during FLACS. Interface systems are divided into applanation and nonapplanation types. The nonapplanation type induces minimal elevation of intraocular pressure (IOP; reportedly less than 40 mm Hg), whereas the applanation type, as used with the Ziemer 8 platform, induces an elevation of IOP of up to 80 mm Hg [8]. It is possible that prostaglandin release is initiated not only through direct shockwaves from laser pulses onto the ciliary body but also through unknown inflammatory processes upon release of the lens protein into the anterior chamber after completion of the capsulotomy or release of cytokines through the clear cornea incision or suction-induced IOP elevation. Schultz et al. found that PGE2 increased after femtosecond laser capsulotomy alone but not after lens fragmentation without capsulotomy [28]. Jun [8] found that the anatomic distance between the laser capsulotomy and the pupil margin was significantly and positively correlated with pupil constriction, although this was contradicted by Popiela et al. [19], who reported sustained mydriasis in eyes with a mean capsulotomy–pupil distance of 0.99 ± 0.29 mm as opposed to decreasing pupil size in patients with a mean capsulotomy–pupil distance of only 0.77 ± 0.7 mm. Popiela et al. suggested that the gas bubbles created during capsulotomy irritated the pupil edge and led to prostaglandin release with subsequent constriction. Therefore, a larger distance protected the pupil margin from irritation through gas bubbles [5,19,26]. In the present study, the distance between the pupil diameter and capsulotomy during suction was greater than 1.5 mm in all cases, as the capsulotomy size was fixed at 5.2 mm. This might explain the observation of sustained mydriasis, despite the fact that no NSAIDs were administered before FLACS.

Of course, differences in the laser technology itself could also be a cause of the variations in pupil behavior during FLACS. “Low-energy” concepts with a high numerical aperture in femtosecond laser optics are an important evolutionary step toward smaller laser spots and thereby reduce collateral damage to the surrounding ocular tissue [29]. The modern low-energy concept combines high repetition rate (>1 MHz) and pulse energies in the nanojoule range, whereas “high-energy” femtosecond lasers emit energy in the microjoule range. Low-energy concepts aim to achieve precise tissue cuts while minimizing mechanical side effects [12,13]. The results of the present study can be explained by the fact that a low-energy laser platform probably produces lower collateral damage to the surrounding tissue, such as mechanical effects of cavitation bubbles, thus resulting in a smaller release of prostaglandins and, thereby, no intraoperative pupil narrowing. In fact, a very recent study on low-pulse energy femtosecond laser pretreatment did not note any additional interleukins but only a small, though statistically significant, increase of prostaglandin release in the anterior chamber compared with conventional phacoemulsification [21]. The researchers analyzed the level of inflammatory parameters 5 minutes after completion of laser pretreatment. A single dose of topical NSAID had been administered 30 minutes before the initiation of cataract surgery [21]. The authors concluded that the decrease in the inflammatory reaction as compared with values reported in the literature was a result of the lower pulse energy femtosecond laser. This finding is one possible explanation for the observation of an overall unchanged pupil area although the role of preoperative NSAID administration could have contributed to the low inflammatory cytokine levels observed by Schwarzenbacher et al Nevertheless, in a 2019 study by Liu et al., FLACS was performed using the same low-energy Femto LDV Z8 laser platform used in the present study, and a significantly higher PGE2 level was induced as compared with conventional phacoemulsification [18]. The authors report clinically relevant pupil constriction. They observed that preoperative administration of NSAIDS reduced the PGE2 surge and occurrence of intraoperative miosis. Additionally, oxidative stress induced during phacoemulsification was measured by an increase in aqueous malondialdehyde and was strongly correlated with the effective phacoemulsification time but not with the femtosecond laser application or NSAID use. Although the patients in Schwarzenbacher et al.’s study were operated under topical anesthesia, patients in the current study and the research by Liu et al. were operated under local peribulbar anesthesia. Peribulbar anesthesia, when including the optic nerve, leads to pupillary dilation via an afferent pupillary defect in itself and blocks reactive miosis from the light of the operating microscope. A major difference between the above-mentioned studies and the current study is the fact that in the latter, no corneal cuts were made with the femtosecond laser. Creating a clear corneal incision with the femtosecond laser is an independent factor in FLACS-induced prostaglandin release [26].

Another possible explanation for the observation of an unchanged pupil area in the current study is the shifting time. When the Ziemer Z8 laser is used, surgery can be continued without any delay after completion of laser pretreatment. Other laser platforms require the patient to be transferred to another surgical table or theater. The increase in time elapsed allows the prostaglandins released after femtosecond laser pretreatment to have an effect on the pupil. This has been examined in different studies, and the results are inconclusive [30]. Schwarzenbacher et al. waited 5 minutes after completion of laser pretreatment and found FLACS-induced miosis [21], whereas Popiela et al. found FLACS-induced miosis but no correlation with their admittedly short shifting time of 4.22 minutes [19]. This was in accordance with the findings by Jun et al., who reported a shifting time of 40 minutes and no correlation with pupillary constriction [8].

The results of the present study are clinically relevant because a smaller pupil size is generally considered challenging for the surgeon and potentially leads to a higher incidence and/or severity of complications after cataract surgery [8,31]. It is, therefore, assumed that the absence of femtosecond laser-associated intraoperative miosis using a low-energy platform increases safety during surgery, makes surgery easier for the cataract surgeon, causes less trauma to the eye, and is therefore beneficial for patients.

The following limitations of this study merit consideration. (1) The mean difference plots show that the mean values were within the equivalence range, but not for every single measurement. Because the variance was comparable between preoperative and posttreatment data, it is assumed that the conclusion of equivalence of pupil sizes is indeed correct. A systematic effect (enlargement or reduction in size) would lead to changes in variance. (2) The study sample was entirely composed of Caucasian individuals. A different pupillary behavior could be suspected in more pigmented irides. (3) No intraoperative measurement of prostaglandins in aqueous humor was obtained. (4) There was a negligible shifting time. (5) One further limitation of the present study is that all study measurements were done under peribulbar anesthesia (as it is performed in 46% of the cataract surgeries in Germany; according to a survey in 2019 [32]). Further studies using other anesthesia methods are necessary to confirm the role of anesthetic method.

The results of the current study are valuable because they demonstrate that sustained mydriasis is possible in FLACS under specific surgical settings. Although further studies are needed, the goal should be to adjust these surgical settings to make FLACS an even more reliable and safe procedure for the benefit of patients.

In summary, this study demonstrates sustained mydriasis that even increased during suction when performing FLACs without preoperative use of NSAIDs. This contradicts the findings of various other studies but can be explained by the differences between the surgical settings of the present study and prior research, including the use of a low-energy, high-frequency laser, omission of femtosecond laser corneal cuts, a large distance between the pupillary margin and capsulotomy, a negligible shifting time, and surgery performed under peribulbar anesthesia.

Supporting information

S1 Data

(XLSX)

Acknowledgments

Meeting presentation: Presented in part at the ESCRS annual meeting, Lisbon, Portugal, October 2017.

Data Availability

All relevant data are within the manuscript and its Supporting information files.

Funding Statement

K.A.P. is funded by the German Federal Ministry of Education and Research (BMBF 01EO1003).

References

  • 1.Dick HB, Schultz T. A review of laser-assisted versus traditional phacoemulsification cataract surgery. Ophthalmol Ther. 2017;6: 7–18. 10.1007/s40123-017-0080-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Ewe SY, Abell RG, Vote BJ. Femtosecond laser-assisted versus phacoemulsification for cataract extraction and intraocular lens implantation: clinical outcomes review. Curr Opin Ophthalmol. 2018;29: 54–60. 10.1097/ICU.0000000000000433 [DOI] [PubMed] [Google Scholar]
  • 3.Grewal DS, Schultz T, Basti S, Dick HB. Femtosecond laser-assisted cataract surgery—current status and future directions. Surv Ophthalmol. 2016;61: 103–131. 10.1016/j.survophthal.2015.09.002 [DOI] [PubMed] [Google Scholar]
  • 4.Nagy Z, Takacs A, Filkorn T, Sarayba M. Initial clinical evaluation of an intraocular femtosecond laser in cataract surgery. J Refract Surg. 2009;25: 1053–1060. 10.3928/1081597X-20091117-04 [DOI] [PubMed] [Google Scholar]
  • 5.Nagy ZZ, Takacs AI, Filkorn T, Kranitz K, Gyenes A, Juhasz E, et al. Complications of femtosecond laser-assisted cataract surgery. J Cataract Refract Surg. 2014;40: 20–28. 10.1016/j.jcrs.2013.08.046 [DOI] [PubMed] [Google Scholar]
  • 6.Roberts TV, Lawless M, Bali SJ, Hodge C, Sutton G. Surgical outcomes and safety of femtosecond laser cataract surgery: a prospective study of 1500 consecutive cases. Ophthalmology. 2013;120: 227–233. 10.1016/j.ophtha.2012.10.026 [DOI] [PubMed] [Google Scholar]
  • 7.Diakonis VF, Yesilirmak N, Sayed-Ahmed IO, Warren DP, Kounis GA, Davis Z, et al. Effects of femtosecond laser-assisted cataract Ppretreatment on pupil diameter: A comparison between three laser platforms. J Refract Surg. 2016;32: 84–88. 10.3928/1081597X-20151229-03 [DOI] [PubMed] [Google Scholar]
  • 8.Jun JH, Hwang KY, Chang SD, Joo CK. Pupil-size alterations induced by photodisruption during femtosecond laser-assisted cataract surgery. J Cataract Refract Surg. 2015;41: 278–285. 10.1016/j.jcrs.2014.10.027 [DOI] [PubMed] [Google Scholar]
  • 9.Diakonis VF, Kontadakis GA, Anagnostopoulos AG, Yesilirmak N, Waren DP, Cabot F, et al. Effects of short-term preoperative topical ketorolac on pupil diameter in eyes undergoing femtosecond laser-assisted capsulotomy. J Refract Surg. 2017;33: 230–234. 10.3928/1081597X-20170111-02 [DOI] [PubMed] [Google Scholar]
  • 10.Jun JH, Yoo YS, Lim SA, Joo CK. Effects of topical ketorolac tromethamine 0.45% on intraoperative miosis and prostaglandin E2 release during femtosecond laser-assisted cataract surgery. J Cataract Refract Surg. 2017;43: 492–497. 10.1016/j.jcrs.2017.01.011 [DOI] [PubMed] [Google Scholar]
  • 11.Bali SJ, Hodge C, Lawless M, Roberts TV, Sutton G. Early experience with the femtosecond laser for cataract surgery. Ophthalmology. 2012;119: 891–899. 10.1016/j.ophtha.2011.12.025 [DOI] [PubMed] [Google Scholar]
  • 12.Mariacher S, Ebner M, Seuthe AM, Januschowski K, Ivanescu C, Opitz N, et al. Femtosecond laser-assisted cataract surgery: First clinical results with special regard to central corneal thickness, endothelial cell count, and aqueous flare levels. J Cataract Refract Surg. 2016;42: 1151–1156. 10.1016/j.jcrs.2016.06.024 [DOI] [PubMed] [Google Scholar]
  • 13.Pajic B, Cvejic Z, Pajic-Eggspuehler B. Cataract surgery performed by high frequency LDV Z8 Femtosecond laser: safety, efficacy, and its physical properties. Sensors (Basel). 2017;17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Liou HL, Brennan NA. Anatomically accurate, finite model eye for optical modeling. J Opt Soc Am A Opt Image Sci Vis. 1997;14: 1684–1695. 10.1364/josaa.14.001684 [DOI] [PubMed] [Google Scholar]
  • 15.Mara CA, Cribbie RA. Paired-samples tests of equivalence. Commun Stat-Simul C. 2012;41: 1928–1943. [Google Scholar]
  • 16.Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987;15: 657–680. 10.1007/BF01068419 [DOI] [PubMed] [Google Scholar]
  • 17.Kiss HJ, Takacs AI, Kranitz K, Sandor GL, Toth G, Gilanyi B, et al. One-day use of preoperative topical nonsteroidal anti-inflammatory drug prevents intraoperative prostaglandin level elevation during femtosecond laser-assisted cataract surgery. Curr Eye Res. 2016;41: 1064–1067. 10.3109/02713683.2015.1092556 [DOI] [PubMed] [Google Scholar]
  • 18.Liu YC, Setiawan M, Ang M, Yam GHF, Mehta JS. Changes in aqueous oxidative stress, prostaglandins, and cytokines: Comparisons of low-energy femtosecond laser-assisted cataract surgery versus conventional phacoemulsification. J Cataract Refract Surg. 2019;45: 196–203. 10.1016/j.jcrs.2018.09.022 [DOI] [PubMed] [Google Scholar]
  • 19.Popiela MZ, Young-Zvandasara T, Nidamanuri P, Moore T, Leccisotti A, Kumar V. Factors influencing pupil behaviour during femtosecond laser assisted cataract surgery. Cont Lens Anterior Eye. 2019;42: 295–298. 10.1016/j.clae.2018.10.010 [DOI] [PubMed] [Google Scholar]
  • 20.Schultz T, Joachim SC, Kuehn M, Dick HB. Changes in prostaglandin levels in patients undergoing femtosecond laser-assisted cataract surgery. J Refract Surg. 2013;29: 742–747. 10.3928/1081597X-20131021-03 [DOI] [PubMed] [Google Scholar]
  • 21.Schwarzenbacher L, Schartmueller D, Leydolt C, Menapace R. Intra-individual comparison of cytokine and prostaglandin levels with and without low-energy, high-frequency femtosecond laser cataract pretreatment following single-dose topical NSAID application. J Cataract Refract Surg. 2020. 10.1097/j.jcrs.0000000000000221 [DOI] [PubMed] [Google Scholar]
  • 22.Yeoh R. Intraoperative miosis in femtosecond laser-assisted cataract surgery. J Cataract Refract Surg. 2014;40: 852–853. 10.1016/j.jcrs.2014.02.026 [DOI] [PubMed] [Google Scholar]
  • 23.Mirshahi A, Ponto KA. Changes in pupil area during low-energy femtosecond laser-assisted cataract surgery. J Ophthalmic Vis Res. 2019;14: 251–256. 10.18502/jovr.v14i3.4780 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Rutkowski PC, Thompson HS. Mydriasis and increased intraocular pressure. II. Iris fluorescein studies. Arch Ophthalmol. 1972;87: 25–29. 10.1001/archopht.1972.01000020027005 [DOI] [PubMed] [Google Scholar]
  • 25.Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol. 2010;55: 108–133. 10.1016/j.survophthal.2009.07.005 [DOI] [PubMed] [Google Scholar]
  • 26.Schultz T, Joachim SC, Stellbogen M, Dick HB. Prostaglandin release during femtosecond laser-assisted cataract surgery: main inducer. J Refract Surg. 2015;31: 78–81. 10.3928/1081597X-20150122-01 [DOI] [PubMed] [Google Scholar]
  • 27.Wang L, Zhang Z, Koch DD, Jia Y, Cao W, Zhang S. Anterior chamber interleukin 1beta, interleukin 6 and prostaglandin E2 in patients undergoing femtosecond laser-assisted cataract surgery. Br J Ophthalmol. 2016;100: 579–582. 10.1136/bjophthalmol-2015-307586 [DOI] [PubMed] [Google Scholar]
  • 28.Schultz T, Joachim SC, Szuler M, Stellbogen M, Dick HB. NSAID Pretreatment inhibits prostaglandin release in femtosecond laser-assisted cataract surgery. J Refract Surg. 2015;31: 791–794. 10.3928/1081597X-20151111-01 [DOI] [PubMed] [Google Scholar]
  • 29.Riau AK, Liu YC, Lwin NC, Ang HP, Tan NY, Yam GH, et al. Comparative study of nJ- and muJ-energy level femtosecond lasers: evaluation of flap adhesion strength, stromal bed quality, and tissue responses. Invest Ophthalmol Vis Sci. 2014;55: 3186–3194. 10.1167/iovs.14-14434 [DOI] [PubMed] [Google Scholar]
  • 30.Dick HB, Gerste RD. Plea for femtosecond laser pre-treatment and cataract surgery in the same room. J Cataract Refract Surg. 2014;40: 499–500. 10.1016/j.jcrs.2014.01.005 [DOI] [PubMed] [Google Scholar]
  • 31.Joseph J, Wang HS. Phacoemulsification with poorly dilated pupils. J Cataract Refract Surg. 1993;19: 551–556. 10.1016/s0886-3350(13)80624-4 [DOI] [PubMed] [Google Scholar]
  • 32.Wenzel M, Dick HB, Scharrer A, Schayan K, Agostini H, Reinhard T. Outpatient and inpatient intraocular surgery 2019: Results of the survey by BDOC, BVA, DGII and DOG. OPHTHALMO SURGERY 2020;32: 340–350. [Google Scholar]

Decision Letter 0

Yu-Chi Liu

10 Nov 2020

PONE-D-20-21038

Perioperative pupil size in low-energy femtosecond laser-assisted cataract surgery

PLOS ONE

Dear Dr. Mirshahi,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Dec 25 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Yu-Chi Liu, M.D

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2.We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

3.Thank you for stating the following in the Acknowledgments Section of your manuscript:

[K.A.P. is funded by the Federal Ministry of Education and Research (BMBF 01EO1003).]

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

 [AM is a consultant to Ziemer Ophthalmics, Biel, Switzerland

Yes: Ziemer assisted in extraction of pictures from the femtosecond laser device.]

Additionally, because some of your funding information pertains to commercial funding, we ask you to provide an updated Competing Interests statement, declaring all sources of commercial funding.

In your Competing Interests statement, please confirm that your commercial funding does not alter your adherence to PLOS ONE Editorial policies and criteria by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.” as detailed online in our guide for authors  http://journals.plos.org/plosone/s/competing-interests.  If this statement is not true and your adherence to PLOS policies on sharing data and materials is altered, please explain how.

Please include the updated Competing Interests Statement and Funding Statement in your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Overall, this is a nice study with a thoughtful and well-researched discussion that contributes to our understanding of the effects of femtosecond laser technology for cataract surgery on pupillary dynamics. Most of my comments here pertain to style and grammatical suggestions.

Line 59-60: Do the authors mean that they generally did not observe pupillary miosis in their experience prior to conducting this study? The way in which it is worded makes it sound almost like a conclusion of the study rather than a reason to perform the study.

Line 149: Perhaps this can be phrased as “A secondary question was whether the values measured during different steps of the laser pretreatment varied from the initial values.”

Line 168: Should be “The mean (±SD), median, minimum[…]”

Line 176: “Change in pupil diameters at different time points{…}”

Line 197-200: Awkward phrasing and grammar.

Line 216: “in contrast to” may be a better phrase than “contradictory to”.

Line 217: I think it would help to specify that this was a study with low energy FLACS.

Line 222-224: Awkward phrasing.

Line 228-229: May be better to word this as “[…]and increased amounts have been measured in FLACS compared to classic phacoemulsification[…]”.

Line 231: “femtolaser” is nonstandard. Should say “femtosecond laser” or abbreviate all instances of “femtosecond laser” to something like “FSL”. This also occurs in Line 346.

Line 235: I suggest “NSAID pretreatment does not appear to completely eliminate FLACS-induced miosis.”

Line 245: Use of “femto” is nonstandard. See above.

Line 295: References to studies with multiple authors should be written with “et al”, as in “in a 2019 study by Liu et al.” This error occurs several times.

Lines 298-302: I believe all these statements are referring to the study by Liu et al., but it becomes less clear with each sentence. I suggest “They observed that preoperative administration of NSAIDS[…]” and “Additionally, oxidative stress induced[…]”, assuming this is what the authors mean.

Line 322-323: This seems like an orphaned sentence. Explanation and sources should be provided for this statement.

Other comments: I personally do not routinely administer peribulbar anesthesia for my cataract surgeries, preferring topical anesthesia especially with my FLACS cases. I wonder if the authors in their discussion can comment further on what extent they believe peribulbar anesthesia could have been a contributing factor in their observations if at all.

Reviewer #2: Line 41: Please reword FLACS has become Staple of modern cataract surgery. There is no evidence FLACS is superior to standard phaco with regards to any clinical outcomes

Line 168:

Please report this is a less confusing way

Mean (SD), median, and range

Line 115: Peribulbar anesthesia ? May be good to state exactly volume and needle used to administer this

Most cataract surgeries in U.S. are done under topical so this study would not be relevant. Authors should mention what percent of cases done with block in Germany If majority are not under topical, this study is not relevant given the block is likely the only reason constriction was not seen.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 May 17;16(5):e0251549. doi: 10.1371/journal.pone.0251549.r002

Author response to Decision Letter 0


13 Jan 2021

We have followed all suggestions by the two reviewers as follows:

Reviewer #1: Overall, this is a nice study with a thoughtful and well-researched discussion that contributes to our understanding of the effects of femtosecond laser technology for cataract surgery on pupillary dynamics. Most of my comments here pertain to style and grammatical suggestions.

1. Line 59-60: Do the authors mean that they generally did not observe pupillary miosis in their experience prior to conducting this study? The way in which it is worded makes it sound almost like a conclusion of the study rather than a reason to perform the study.

� Thank you for this comment. We changed the sentence to “However, according to our personal experience in the clinic we hypothesized that no miosis induction through laser pretreatment occurs when using the Ziemer Z8 laser platform.”

2. Line 149: Perhaps this can be phrased as “A secondary question was whether the values measured during different steps of the laser pretreatment varied from the initial values.”

� The sentence was changed as proposed.

3. Line 168: Should be “The mean (±SD), median, minimum[…]”

� We changed this as proposed.

4. Line 176: “Change in pupil diameters at different time points{…}”

� The sentence was corrected accordingly.

5. Line 197-200: Awkward phrasing and grammar.

� The sentence was changed to “We could not detect any equivalence of the preoperative pupil diameters to those measured immediately after application of suction, after completion of lens fragmentation, or after completion of laser capsulotomy (suction applied during those measurements, TOST procedure, all p>0.05).”

6. Line 216: “in contrast to” may be a better phrase than “contradictory to”.

� We changed it as proposed.

7. Line 217: I think it would help to specify that this was a study with low energy FLACS.

� We added this.

8. Line 222-224: Awkward phrasing.

� The sentence was changed to “This is a physiologic phenomenon which is explained both by the afferent pupillary defect and also by an impairment in the iris sphincter (due to an intraocular pressure elevation greater than the systolic ophthalmic artery pressure)”

9. Line 228-229: May be better to word this as “[…]and increased amounts have been measured in FLACS compared to classic phacoemulsification[…]”.

� We changed the sentence as proposed.

10. Line 231: “femtolaser” is nonstandard. Should say “femtosecond laser” or abbreviate all instances of “femtosecond laser” to something like “FSL”. This also occurs in Line 346.

� We replaced “femtolaser” by “femtosecond laser” throughout the manuscript.

11. Line 235: I suggest “NSAID pretreatment does not appear to completely eliminate FLACS-induced miosis.”

� We changed the sentence as proposed.

12. Line 245: Use of “femto” is nonstandard. See above.

� We changed this throughout the paper.

13. Line 295: References to studies with multiple authors should be written with “et al”, as in “in a 2019 study by Liu et al.” This error occurs several times.

� We corrected this throughout the manuscript.

14. Lines 298-302: I believe all these statements are referring to the study by Liu et al., but it becomes less clear with each sentence. I suggest “They observed that preoperative administration of NSAIDS[…]” and “Additionally, oxidative stress induced[…]”, assuming this is what the authors mean.

� The sentences were revised as proposed.

15. Line 322-323: This seems like an orphaned sentence. Explanation and sources should be provided for this statement.

� The sentence referred to the sentence one line above. In fact, however, the wording was awkward. We therefore reworded the sentence to better reflect the reference to the study.

16. Other comments: I personally do not routinely administer peribulbar anesthesia for my cataract surgeries, preferring topical anesthesia especially with my FLACS cases. I wonder if the authors in their discussion can comment further on what extent they believe peribulbar anesthesia could have been a contributing factor in their observations if at all.

� We added the following paragraph to the discussion: “One further limitation of the present study is that all study measurements were done under peribulbar anesthesia (as it is performed in 46% of the cataract surgeries in Germany; according to a survey of 2019 by the German Society of Intraocular Implants and Refractive Surgery, DGII […]). We do not believe that the results would have been different under other anesthesia methods (incl. topical); However, further studies using other anesthesia methods are necessary to confirm the assumed.” (lines 338-344)

17. Reviewer #2: Line 41: Please reword FLACS has become Staple of modern cataract surgery. There is no evidence FLACS is superior to standard phaco with regards to any clinical outcomes

� We changed the sentence to: “During the past decade, femtosecond laser-assisted cataract surgery (FLACS) has gained increasing popularity”

18. Line 168: Please report this is a less confusing way; Mean (SD), median, and range

� This has been changed (see #3).

19. Line 115: Peribulbar anesthesia ? May be good to state exactly volume and needle used to administer this.

� We added the details (ieach 3 ml of Mepivacaine 2% and Bupivacaine 0.75% and 75 IE hyaluronidase with a 22 Gauge needle). Lines 116-118

20. Most cataract surgeries in U.S. are done under topical so this study would not be relevant. Authors should mention what percent of cases done with block in Germany If majority are not under topical, this study is not relevant given the block is likely the only reason constriction was not seen.

� We added the following paragraph to the discussion: “One further limitation of the present study is that all study measurements were done under peribulbar anesthesia (as it is performed in 46% of the cataract surgeries in Germany; according to a survey of 2019 by the German Society of Intraocular Implants and Refractive Surgery, DGII […]). We do not believe that the results would have been different under other anesthesia methods (incl. topical); However, further studies using other anesthesia methods are necessary to confirm the assumed.” (lines 338-344)

Decision Letter 1

Yu-Chi Liu

16 Feb 2021

PONE-D-20-21038R1

Perioperative pupil size in low-energy femtosecond laser-assisted cataract surgery

PLOS ONE

Dear Dr. Mirshahi,

Thank you for submitting your manuscript to PLOS ONE. The reviewers have raised some more comments. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Apr 02 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Yu-Chi Liu, MD, MCI

Academic Editor

PLOS ONE

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: No

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Additional minor recommendations and comments:

Line 253: “Although all three laser platforms […]” can be the start of a new paragraph.

Line 293: If subjects were given a dose of NSAID before surgery, I’m not sure how it can be concluded that the decrease in inflammatory reaction results from the use of lower pulse energy FSL and not from the use of pre-operative NSAIDs. Authors should confirm whether this was in fact a conclusion of the cited study and/or clarify this statement.

Line 323-324: This is still an orphaned sentence and does not appear to have been modified from the original. I’m uncertain as to its relevance, but it can probably be incorporated into another paragraph earlier in the manuscript if you choose to keep it.

Line 342: There is no reason to abbreviate “including”. The semicolon should be a period.

Lines 339-343: I would advise caution with this broad assumption as it seems to directly contradict your statement on the pupillary effects of peribulbar anesthesia in Lines 306-308.

Reviewer #2: It is not accurate to say peribulbar anesthesia does not affect pupil size. This is a fatal flaw of the manuscript. If 46% of cases in Germany done under peribulbar, then you should review the results of topical as well. Not sure why those with topical anesthesia were excluded from the study.

https://pubmed.ncbi.nlm.nih.gov/23879851/

https://bjo.bmj.com/content/bjophthalmol/78/1/41.full.pdf

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 May 17;16(5):e0251549. doi: 10.1371/journal.pone.0251549.r004

Author response to Decision Letter 1


22 Mar 2021

Response to Reviewers

Reviewer #1: Additional minor recommendations and comments:

Line 253: “Although all three laser platforms […]” can be the start of

a new paragraph.

--> A new paragraph was included as recommended.

Line 293: If subjects were given a dose of NSAID before surgery, I’m

not sure how it can be concluded that the decrease in inflammatory

reaction results from the use of lower pulse energy FSL and not from

the use of pre-operative NSAIDs. Authors should confirm whether this

was in fact a conclusion of the cited study and/or clarify this

statement.

--> As stated in the section “surgical technique” no NSAID was given to any patient before surgery in our study.

--> With regards to Schwarzenbacher’s paper we acknowledge the anti-inflammatory effect of preoperative NSAID; We believe the authors’ conclusion is based on the fact that the measured inflammatory cytokine levels were lower than reported in other studies using other laser platforms. Our wording is exactly the conclusion of the cited study. Nevertheless, we added this issue to the discussion (Line 296-297)

Line 323-324: This is still an orphaned sentence and does not appear

to have been modified from the original. I’m uncertain as to its

relevance, but it can probably be incorporated into another paragraph

earlier in the manuscript if you choose to keep it.

--> The sentence was deleted.

Line 342: There is no reason to abbreviate “including”. The semicolon

should be a period.

-->The changes were made as recommended.

Lines 339-343: I would advise caution with this broad assumption as it

seems to directly contradict your statement on the pupillary effects

of peribulbar anesthesia in Lines 306-308.

--> We revised the wording and hope it is more suitable now. Lines 342-346

Reviewer #2:

It is not accurate to say peribulbar anesthesia does not

affect pupil size. This is a fatal flaw of the manuscript. If 46% of

cases in Germany done under peribulbar, then you should review the

results of topical as well. Not sure why those with topical anesthesia

were excluded from the study.

The authors do not claim peribulbar anesthesia does not affect the pupil size. We just believe the results of our study would have been similar under other anesthetic methods. Nevertheless, we revised the wording and hope it is more suitable (Lines 342-346). The authors perform almost all cataract surgeries under peribulbar anesthesia, thus the paper is solely representing those cases.

Attachment

Submitted filename: R2_Response to Reviewers.docx

Decision Letter 2

Yu-Chi Liu

29 Apr 2021

Perioperative pupil size in low-energy femtosecond laser-assisted cataract surgery

PONE-D-20-21038R2

Dear Dr. Mirshahi,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Yu-Chi Liu, M.D

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: Comments addressed.

I have stated the limitations. In the U.S. most cataract cases are performed under topical, so I think studying this in topical cases would be more helpful.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Acceptance letter

Yu-Chi Liu

7 May 2021

PONE-D-20-21038R2

Perioperative pupil size in low-energy femtosecond laser-assisted cataract surgery

Dear Dr. Mirshahi:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Yu-Chi Liu

Academic Editor

PLOS ONE


Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES